* Cytosorbents Corp is expected to show a rise in quarterly revenue when it reports results on May 9 for the period ending March 31 2024
* The Princeton New Jersey-based company is expected to report a 3.5% increase in revenue to $9.785 million from $9.45 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Cytosorbents Corp is for a loss of 12 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Cytosorbents Corp is $4.00, above its last closing price of $0.93.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.10 -0.14 -0.13 Beat 5.5
Sep. 30 2023 -0.15 -0.14 -0.21 Missed -52.2
Jun. 30 2023 -0.11 -0.11 -0.14 Missed -24.4
Mar. 31 2023 -0.13 -0.13 -0.17 Missed -34.2
Dec. -0.18 -0.17 -0.02 Beat 88.1
31 2022
Sep. 30 2022 -0.16 -0.16 -0.28 Missed -70.7
Jun. 30 2022 -0.14 -0.13 -0.25 Missed -86.9
Mar. 31 2022 -0.12 -0.12 -0.21 Missed -71.4
This summary was machine generated May 8 at 02:22 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments